news
Novel inhibitor developed to combat HER2-positive breast cancer
The inhibitor, HVH-2930, effectively induced apoptosis in breast cancer cells without initiating the heat shock response.
List view / Grid view
Cancer Research
news
Assessing the risk of HCC with machine learning
A novel screening tool may increase the five-year survival rate of hepatocellular carcinoma patients to 90 percent.
news
New 3D genomic profiling technique details PanINs
Researchers have developed a 3D approach to improve the characterisation of pancreatic intraepithelial neoplasias.
news
Cancer dependencies missed by some CRISPR guides
Scientists discovered that, depending on germline variation, CRISPR-based experiments can result in false negatives.
article
New algorithm forms atlas of histomorphological phenotypes
The algorithm can accurately diagnose cases of lung adenocarcinoma, determining structural features that are statistically most significant for assessing disease severity and likelihood of tumour recurrence.
article
A T cell receptor immunotherapy against a novel target
In this Q&A, Associate Director, Research at Immunocore, Dr Ana Pereira Ribeiro, talks about IMC-R117C, a T cell receptor bispecific immunotherapy directed towards a novel target, PIWIL1, and about to enter Phase I testing in colorectal and gastrointestinal cancers.
news
Macrophage-mediated phagocytosis: treating solid tumours
A new immunotherapy approach combining co-engineered T cells and antibodies enhances phagocytosis of tumour cells.
news
Proteogenomics: finding targets for never-smoker lung cancer
Through multi-omics analysis, researchers find that oestrogen signalling could be a target for never-smoker lung cancer cases.
article
Leveraging ADCs in precision oncology strategy
In this Q&A, senior leaders at Caris Life Sciences discuss how the company is advancing precision medicine by integrating ADCs into patient-specific cancer treatment plans, focusing on novel target discovery through comprehensive molecular profiling and clinico-genomic data.
news
Reprogramming immune-suppressive macrophages in tumours
A novel drug, JHU083, turns into its active, glutamine-blocking form inside tumours, shrinking prostate and bladder cancers in mice.
article
Improving treatment responses to solid tumours with trispecific TCEs
Following Zymeworks’ presentation at AACR 2024, in this Q&A, Dr Nina Weisser explains how the next generation trispecific T cell engager platform with integrated CD28 costimulation is engineered to tackle solid tumours.
news
Ovarian cancer: CBR-5884 demonstrates promising antitumour effects
In assays and patient-derived organoids, the small molecule inhibitor CBR-5884 successfully treated epithelial ovarian cancer.
news
Breast cancer genetic variants in women of African ancestry
Researchers identified variants in three loci that were associated with risk of triple-negative breast cancer.
article
Utilising engineered peptides for immunotherapy
In this Q&A, Dr DaeYong Lee discusses how a new method for building up natural immune response could lead to new immunotherapy drugs with safer toxicity profiles.
article
Overcoming the limitations of current drug discovery approaches
In this Q&A, Simon Kerry, CEO of Curve Therapeutics, shares the company’s recent milestones, insights into the innovative Microcycle platform, and how Curve plans to remain on the cutting edge of drug discovery.